nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A5—Teniposide—lymphatic system cancer	0.191	0.271	CbGbCtD
Rivaroxaban—CYP3A5—Vincristine—lymphatic system cancer	0.0919	0.131	CbGbCtD
Rivaroxaban—ABCB1—Mitoxantrone—lymphatic system cancer	0.0869	0.123	CbGbCtD
Rivaroxaban—CYP3A4—Cytarabine—lymphatic system cancer	0.0756	0.107	CbGbCtD
Rivaroxaban—CYP3A4—Teniposide—lymphatic system cancer	0.0745	0.106	CbGbCtD
Rivaroxaban—ABCB1—Vincristine—lymphatic system cancer	0.0598	0.085	CbGbCtD
Rivaroxaban—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0521	0.074	CbGbCtD
Rivaroxaban—ABCB1—Methotrexate—lymphatic system cancer	0.0362	0.0515	CbGbCtD
Rivaroxaban—CYP3A4—Vincristine—lymphatic system cancer	0.0358	0.0509	CbGbCtD
Rivaroxaban—Blood bilirubin increased—Mitoxantrone—lymphatic system cancer	0.00206	0.00695	CcSEcCtD
Rivaroxaban—Angina pectoris—Fludarabine—lymphatic system cancer	0.002	0.00675	CcSEcCtD
Rivaroxaban—Haemoglobin—Teniposide—lymphatic system cancer	0.00188	0.00635	CcSEcCtD
Rivaroxaban—Haemorrhage—Teniposide—lymphatic system cancer	0.00187	0.00631	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00187	0.0063	CcSEcCtD
Rivaroxaban—Blood urea increased—Mitoxantrone—lymphatic system cancer	0.00184	0.00621	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00181	0.00613	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0018	0.00608	CcSEcCtD
Rivaroxaban—Renal failure—Fludarabine—lymphatic system cancer	0.0018	0.00608	CcSEcCtD
Rivaroxaban—Infection—Mechlorethamine—lymphatic system cancer	0.00179	0.00604	CcSEcCtD
Rivaroxaban—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00178	0.00601	CcSEcCtD
Rivaroxaban—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.00176	0.00594	CcSEcCtD
Rivaroxaban—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00175	0.00591	CcSEcCtD
Rivaroxaban—Haematuria—Fludarabine—lymphatic system cancer	0.00175	0.00589	CcSEcCtD
Rivaroxaban—Epistaxis—Fludarabine—lymphatic system cancer	0.00173	0.00583	CcSEcCtD
Rivaroxaban—Swelling—Carmustine—lymphatic system cancer	0.00172	0.00582	CcSEcCtD
Rivaroxaban—Sinusitis—Fludarabine—lymphatic system cancer	0.00172	0.0058	CcSEcCtD
Rivaroxaban—Haemoglobin—Fludarabine—lymphatic system cancer	0.00165	0.00558	CcSEcCtD
Rivaroxaban—Haemorrhage—Fludarabine—lymphatic system cancer	0.00164	0.00555	CcSEcCtD
Rivaroxaban—Swelling—Mitoxantrone—lymphatic system cancer	0.0016	0.00541	CcSEcCtD
Rivaroxaban—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00155	0.00525	CcSEcCtD
Rivaroxaban—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00153	0.00517	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00152	0.00513	CcSEcCtD
Rivaroxaban—Anaemia—Teniposide—lymphatic system cancer	0.0015	0.00508	CcSEcCtD
Rivaroxaban—Pain in extremity—Vincristine—lymphatic system cancer	0.00145	0.0049	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00141	0.00477	CcSEcCtD
Rivaroxaban—Chest pain—Teniposide—lymphatic system cancer	0.00139	0.00468	CcSEcCtD
Rivaroxaban—Oedema—Teniposide—lymphatic system cancer	0.00133	0.00449	CcSEcCtD
Rivaroxaban—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00133	0.00448	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00133	0.00448	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00132	0.00447	CcSEcCtD
Rivaroxaban—Anaemia—Fludarabine—lymphatic system cancer	0.00132	0.00446	CcSEcCtD
Rivaroxaban—Infection—Teniposide—lymphatic system cancer	0.00132	0.00446	CcSEcCtD
Rivaroxaban—Tachycardia—Teniposide—lymphatic system cancer	0.0013	0.00438	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00129	0.00436	CcSEcCtD
Rivaroxaban—Malaise—Fludarabine—lymphatic system cancer	0.00129	0.00436	CcSEcCtD
Rivaroxaban—Haematuria—Bleomycin—lymphatic system cancer	0.00128	0.00432	CcSEcCtD
Rivaroxaban—Pruritus—Mechlorethamine—lymphatic system cancer	0.00127	0.0043	CcSEcCtD
Rivaroxaban—Hypotension—Teniposide—lymphatic system cancer	0.00124	0.00419	CcSEcCtD
Rivaroxaban—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00123	0.00416	CcSEcCtD
Rivaroxaban—Haemoglobin—Bleomycin—lymphatic system cancer	0.00121	0.00409	CcSEcCtD
Rivaroxaban—Haemorrhage—Bleomycin—lymphatic system cancer	0.0012	0.00407	CcSEcCtD
Rivaroxaban—Discomfort—Fludarabine—lymphatic system cancer	0.0012	0.00406	CcSEcCtD
Rivaroxaban—Dyspnoea—Teniposide—lymphatic system cancer	0.00118	0.004	CcSEcCtD
Rivaroxaban—Oedema—Fludarabine—lymphatic system cancer	0.00117	0.00394	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00117	0.00394	CcSEcCtD
Rivaroxaban—Infection—Fludarabine—lymphatic system cancer	0.00116	0.00392	CcSEcCtD
Rivaroxaban—Renal failure—Carmustine—lymphatic system cancer	0.00115	0.00389	CcSEcCtD
Rivaroxaban—Vomiting—Mechlorethamine—lymphatic system cancer	0.00115	0.00387	CcSEcCtD
Rivaroxaban—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00114	0.00387	CcSEcCtD
Rivaroxaban—Urinary tract infection—Carmustine—lymphatic system cancer	0.00114	0.00385	CcSEcCtD
Rivaroxaban—Rash—Mechlorethamine—lymphatic system cancer	0.00114	0.00384	CcSEcCtD
Rivaroxaban—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00113	0.00383	CcSEcCtD
Rivaroxaban—Feeling abnormal—Teniposide—lymphatic system cancer	0.00109	0.0037	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00109	0.00367	CcSEcCtD
Rivaroxaban—Renal failure—Mitoxantrone—lymphatic system cancer	0.00107	0.00361	CcSEcCtD
Rivaroxaban—Nausea—Mechlorethamine—lymphatic system cancer	0.00107	0.00361	CcSEcCtD
Rivaroxaban—Jaundice—Mitoxantrone—lymphatic system cancer	0.00106	0.00358	CcSEcCtD
Rivaroxaban—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00106	0.00357	CcSEcCtD
Rivaroxaban—Haemoglobin—Carmustine—lymphatic system cancer	0.00106	0.00357	CcSEcCtD
Rivaroxaban—Urticaria—Teniposide—lymphatic system cancer	0.00106	0.00356	CcSEcCtD
Rivaroxaban—Haemorrhage—Carmustine—lymphatic system cancer	0.00105	0.00355	CcSEcCtD
Rivaroxaban—Abdominal pain—Teniposide—lymphatic system cancer	0.00105	0.00355	CcSEcCtD
Rivaroxaban—Dyspnoea—Fludarabine—lymphatic system cancer	0.00104	0.00351	CcSEcCtD
Rivaroxaban—Haematuria—Mitoxantrone—lymphatic system cancer	0.00104	0.00351	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00103	0.00349	CcSEcCtD
Rivaroxaban—Dyspepsia—Fludarabine—lymphatic system cancer	0.00103	0.00347	CcSEcCtD
Rivaroxaban—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00102	0.00345	CcSEcCtD
Rivaroxaban—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00102	0.00343	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00101	0.0034	CcSEcCtD
Rivaroxaban—Fatigue—Fludarabine—lymphatic system cancer	0.00101	0.0034	CcSEcCtD
Rivaroxaban—Constipation—Fludarabine—lymphatic system cancer	0.000998	0.00337	CcSEcCtD
Rivaroxaban—Pain—Fludarabine—lymphatic system cancer	0.000998	0.00337	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000991	0.00335	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000986	0.00333	CcSEcCtD
Rivaroxaban—Urethral disorder—Vincristine—lymphatic system cancer	0.000984	0.00332	CcSEcCtD
Rivaroxaban—Eye disorder—Carmustine—lymphatic system cancer	0.000983	0.00332	CcSEcCtD
Rivaroxaban—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000983	0.00332	CcSEcCtD
Rivaroxaban—Hypersensitivity—Teniposide—lymphatic system cancer	0.000979	0.0033	CcSEcCtD
Rivaroxaban—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000978	0.0033	CcSEcCtD
Rivaroxaban—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000978	0.0033	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000973	0.00329	CcSEcCtD
Rivaroxaban—Anaemia—Bleomycin—lymphatic system cancer	0.000969	0.00327	CcSEcCtD
Rivaroxaban—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000962	0.00325	CcSEcCtD
Rivaroxaban—Asthenia—Teniposide—lymphatic system cancer	0.000953	0.00322	CcSEcCtD
Rivaroxaban—Malaise—Bleomycin—lymphatic system cancer	0.000946	0.00319	CcSEcCtD
Rivaroxaban—Pruritus—Teniposide—lymphatic system cancer	0.00094	0.00317	CcSEcCtD
Rivaroxaban—Cardiac disorder—Vincristine—lymphatic system cancer	0.000932	0.00315	CcSEcCtD
Rivaroxaban—Angiopathy—Vincristine—lymphatic system cancer	0.000911	0.00308	CcSEcCtD
Rivaroxaban—Diarrhoea—Teniposide—lymphatic system cancer	0.000909	0.00307	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000905	0.00306	CcSEcCtD
Rivaroxaban—Chest pain—Bleomycin—lymphatic system cancer	0.000893	0.00302	CcSEcCtD
Rivaroxaban—Back pain—Carmustine—lymphatic system cancer	0.000885	0.00299	CcSEcCtD
Rivaroxaban—Discomfort—Bleomycin—lymphatic system cancer	0.000882	0.00298	CcSEcCtD
Rivaroxaban—Ecchymosis—Methotrexate—lymphatic system cancer	0.000877	0.00296	CcSEcCtD
Rivaroxaban—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00086	0.0029	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000856	0.00289	CcSEcCtD
Rivaroxaban—Oedema—Bleomycin—lymphatic system cancer	0.000856	0.00289	CcSEcCtD
Rivaroxaban—Infection—Bleomycin—lymphatic system cancer	0.00085	0.00287	CcSEcCtD
Rivaroxaban—Anaemia—Carmustine—lymphatic system cancer	0.000846	0.00286	CcSEcCtD
Rivaroxaban—Back pain—Vincristine—lymphatic system cancer	0.000845	0.00285	CcSEcCtD
Rivaroxaban—Vomiting—Teniposide—lymphatic system cancer	0.000844	0.00285	CcSEcCtD
Rivaroxaban—Asthenia—Fludarabine—lymphatic system cancer	0.000837	0.00283	CcSEcCtD
Rivaroxaban—Rash—Teniposide—lymphatic system cancer	0.000837	0.00283	CcSEcCtD
Rivaroxaban—Dermatitis—Teniposide—lymphatic system cancer	0.000837	0.00283	CcSEcCtD
Rivaroxaban—Headache—Teniposide—lymphatic system cancer	0.000832	0.00281	CcSEcCtD
Rivaroxaban—Pruritus—Fludarabine—lymphatic system cancer	0.000826	0.00279	CcSEcCtD
Rivaroxaban—Back pain—Mitoxantrone—lymphatic system cancer	0.000823	0.00278	CcSEcCtD
Rivaroxaban—Anaemia—Vincristine—lymphatic system cancer	0.000808	0.00273	CcSEcCtD
Rivaroxaban—Hypotension—Bleomycin—lymphatic system cancer	0.0008	0.0027	CcSEcCtD
Rivaroxaban—Diarrhoea—Fludarabine—lymphatic system cancer	0.000799	0.0027	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00079	0.00267	CcSEcCtD
Rivaroxaban—Nausea—Teniposide—lymphatic system cancer	0.000789	0.00266	CcSEcCtD
Rivaroxaban—Anaemia—Mitoxantrone—lymphatic system cancer	0.000787	0.00266	CcSEcCtD
Rivaroxaban—Chest pain—Carmustine—lymphatic system cancer	0.000779	0.00263	CcSEcCtD
Rivaroxaban—Malaise—Mitoxantrone—lymphatic system cancer	0.000767	0.00259	CcSEcCtD
Rivaroxaban—Dyspnoea—Bleomycin—lymphatic system cancer	0.000763	0.00258	CcSEcCtD
Rivaroxaban—Renal failure acute—Methotrexate—lymphatic system cancer	0.000763	0.00258	CcSEcCtD
Rivaroxaban—Oedema—Carmustine—lymphatic system cancer	0.000747	0.00252	CcSEcCtD
Rivaroxaban—Infection—Carmustine—lymphatic system cancer	0.000742	0.00251	CcSEcCtD
Rivaroxaban—Vomiting—Fludarabine—lymphatic system cancer	0.000742	0.00251	CcSEcCtD
Rivaroxaban—Rash—Fludarabine—lymphatic system cancer	0.000736	0.00249	CcSEcCtD
Rivaroxaban—Dermatitis—Fludarabine—lymphatic system cancer	0.000735	0.00248	CcSEcCtD
Rivaroxaban—Pain—Bleomycin—lymphatic system cancer	0.000732	0.00247	CcSEcCtD
Rivaroxaban—Headache—Fludarabine—lymphatic system cancer	0.000731	0.00247	CcSEcCtD
Rivaroxaban—Tachycardia—Carmustine—lymphatic system cancer	0.000729	0.00246	CcSEcCtD
Rivaroxaban—Chest pain—Mitoxantrone—lymphatic system cancer	0.000724	0.00245	CcSEcCtD
Rivaroxaban—Discomfort—Mitoxantrone—lymphatic system cancer	0.000716	0.00242	CcSEcCtD
Rivaroxaban—Oedema—Vincristine—lymphatic system cancer	0.000713	0.00241	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000713	0.00241	CcSEcCtD
Rivaroxaban—Infection—Vincristine—lymphatic system cancer	0.000708	0.00239	CcSEcCtD
Rivaroxaban—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000705	0.00238	CcSEcCtD
Rivaroxaban—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000704	0.00238	CcSEcCtD
Rivaroxaban—Nervous system disorder—Vincristine—lymphatic system cancer	0.000699	0.00236	CcSEcCtD
Rivaroxaban—Hypotension—Carmustine—lymphatic system cancer	0.000698	0.00236	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000695	0.00235	CcSEcCtD
Rivaroxaban—Oedema—Mitoxantrone—lymphatic system cancer	0.000695	0.00235	CcSEcCtD
Rivaroxaban—Nausea—Fludarabine—lymphatic system cancer	0.000693	0.00234	CcSEcCtD
Rivaroxaban—Infection—Mitoxantrone—lymphatic system cancer	0.00069	0.00233	CcSEcCtD
Rivaroxaban—Shock—Mitoxantrone—lymphatic system cancer	0.000683	0.00231	CcSEcCtD
Rivaroxaban—Urticaria—Bleomycin—lymphatic system cancer	0.00068	0.0023	CcSEcCtD
Rivaroxaban—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000678	0.00229	CcSEcCtD
Rivaroxaban—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000675	0.00228	CcSEcCtD
Rivaroxaban—Hypotension—Vincristine—lymphatic system cancer	0.000666	0.00225	CcSEcCtD
Rivaroxaban—Dyspnoea—Carmustine—lymphatic system cancer	0.000666	0.00225	CcSEcCtD
Rivaroxaban—Hypotension—Mitoxantrone—lymphatic system cancer	0.000649	0.00219	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000645	0.00218	CcSEcCtD
Rivaroxaban—Constipation—Carmustine—lymphatic system cancer	0.000639	0.00216	CcSEcCtD
Rivaroxaban—Pain—Carmustine—lymphatic system cancer	0.000639	0.00216	CcSEcCtD
Rivaroxaban—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000631	0.00213	CcSEcCtD
Rivaroxaban—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000619	0.00209	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000616	0.00208	CcSEcCtD
Rivaroxaban—Feeling abnormal—Carmustine—lymphatic system cancer	0.000616	0.00208	CcSEcCtD
Rivaroxaban—Fatigue—Vincristine—lymphatic system cancer	0.000615	0.00208	CcSEcCtD
Rivaroxaban—Asthenia—Bleomycin—lymphatic system cancer	0.000614	0.00207	CcSEcCtD
Rivaroxaban—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000611	0.00206	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000611	0.00206	CcSEcCtD
Rivaroxaban—Constipation—Vincristine—lymphatic system cancer	0.00061	0.00206	CcSEcCtD
Rivaroxaban—Pain—Vincristine—lymphatic system cancer	0.00061	0.00206	CcSEcCtD
Rivaroxaban—Pruritus—Bleomycin—lymphatic system cancer	0.000606	0.00204	CcSEcCtD
Rivaroxaban—Fatigue—Mitoxantrone—lymphatic system cancer	0.000599	0.00202	CcSEcCtD
Rivaroxaban—Constipation—Mitoxantrone—lymphatic system cancer	0.000594	0.00201	CcSEcCtD
Rivaroxaban—Pain—Mitoxantrone—lymphatic system cancer	0.000594	0.00201	CcSEcCtD
Rivaroxaban—Abdominal pain—Carmustine—lymphatic system cancer	0.000591	0.00199	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000583	0.00197	CcSEcCtD
Rivaroxaban—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000572	0.00193	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000568	0.00192	CcSEcCtD
Rivaroxaban—Abdominal pain—Vincristine—lymphatic system cancer	0.000564	0.0019	CcSEcCtD
Rivaroxaban—Urticaria—Mitoxantrone—lymphatic system cancer	0.000552	0.00186	CcSEcCtD
Rivaroxaban—Hypersensitivity—Carmustine—lymphatic system cancer	0.00055	0.00186	CcSEcCtD
Rivaroxaban—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000549	0.00185	CcSEcCtD
Rivaroxaban—Vomiting—Bleomycin—lymphatic system cancer	0.000544	0.00184	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—lymphatic system cancer	0.000543	0.00183	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—lymphatic system cancer	0.000543	0.00183	CcSEcCtD
Rivaroxaban—Rash—Bleomycin—lymphatic system cancer	0.00054	0.00182	CcSEcCtD
Rivaroxaban—Dermatitis—Bleomycin—lymphatic system cancer	0.000539	0.00182	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000538	0.00182	CcSEcCtD
Rivaroxaban—Asthenia—Carmustine—lymphatic system cancer	0.000536	0.00181	CcSEcCtD
Rivaroxaban—Renal failure—Methotrexate—lymphatic system cancer	0.000533	0.0018	CcSEcCtD
Rivaroxaban—Hypersensitivity—Vincristine—lymphatic system cancer	0.000525	0.00177	CcSEcCtD
Rivaroxaban—Haematuria—Methotrexate—lymphatic system cancer	0.000517	0.00175	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000513	0.00173	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—lymphatic system cancer	0.000512	0.00173	CcSEcCtD
Rivaroxaban—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000512	0.00173	CcSEcCtD
Rivaroxaban—Asthenia—Vincristine—lymphatic system cancer	0.000512	0.00173	CcSEcCtD
Rivaroxaban—Diarrhoea—Carmustine—lymphatic system cancer	0.000511	0.00173	CcSEcCtD
Rivaroxaban—Nausea—Bleomycin—lymphatic system cancer	0.000508	0.00172	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000506	0.00171	CcSEcCtD
Rivaroxaban—Asthenia—Mitoxantrone—lymphatic system cancer	0.000498	0.00168	CcSEcCtD
Rivaroxaban—Dizziness—Carmustine—lymphatic system cancer	0.000494	0.00167	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—lymphatic system cancer	0.00049	0.00165	CcSEcCtD
Rivaroxaban—Diarrhoea—Vincristine—lymphatic system cancer	0.000488	0.00165	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—lymphatic system cancer	0.000487	0.00164	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—lymphatic system cancer	0.000487	0.00164	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000481	0.00162	CcSEcCtD
Rivaroxaban—Urethral disorder—Methotrexate—lymphatic system cancer	0.000477	0.00161	CcSEcCtD
Rivaroxaban—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000475	0.0016	CcSEcCtD
Rivaroxaban—Vomiting—Carmustine—lymphatic system cancer	0.000475	0.0016	CcSEcCtD
Rivaroxaban—Dizziness—Vincristine—lymphatic system cancer	0.000472	0.00159	CcSEcCtD
Rivaroxaban—Rash—Carmustine—lymphatic system cancer	0.000471	0.00159	CcSEcCtD
Rivaroxaban—Dermatitis—Carmustine—lymphatic system cancer	0.000471	0.00159	CcSEcCtD
Rivaroxaban—Headache—Carmustine—lymphatic system cancer	0.000468	0.00158	CcSEcCtD
Rivaroxaban—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000461	0.00156	CcSEcCtD
Rivaroxaban—Eye disorder—Methotrexate—lymphatic system cancer	0.000455	0.00154	CcSEcCtD
Rivaroxaban—Vomiting—Vincristine—lymphatic system cancer	0.000453	0.00153	CcSEcCtD
Rivaroxaban—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000452	0.00153	CcSEcCtD
Rivaroxaban—Rash—Vincristine—lymphatic system cancer	0.00045	0.00152	CcSEcCtD
Rivaroxaban—Dermatitis—Vincristine—lymphatic system cancer	0.000449	0.00152	CcSEcCtD
Rivaroxaban—Headache—Vincristine—lymphatic system cancer	0.000447	0.00151	CcSEcCtD
Rivaroxaban—Nausea—Carmustine—lymphatic system cancer	0.000444	0.0015	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—lymphatic system cancer	0.000442	0.00149	CcSEcCtD
Rivaroxaban—Vomiting—Mitoxantrone—lymphatic system cancer	0.000442	0.00149	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—lymphatic system cancer	0.00044	0.00149	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000439	0.00148	CcSEcCtD
Rivaroxaban—Rash—Mitoxantrone—lymphatic system cancer	0.000438	0.00148	CcSEcCtD
Rivaroxaban—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000438	0.00148	CcSEcCtD
Rivaroxaban—Headache—Mitoxantrone—lymphatic system cancer	0.000435	0.00147	CcSEcCtD
Rivaroxaban—Nausea—Vincristine—lymphatic system cancer	0.000424	0.00143	CcSEcCtD
Rivaroxaban—Nausea—Mitoxantrone—lymphatic system cancer	0.000413	0.00139	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—lymphatic system cancer	0.00041	0.00139	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000393	0.00133	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—lymphatic system cancer	0.000392	0.00132	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—lymphatic system cancer	0.000382	0.00129	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—lymphatic system cancer	0.000361	0.00122	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000358	0.00121	CcSEcCtD
Rivaroxaban—Discomfort—Methotrexate—lymphatic system cancer	0.000357	0.0012	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000346	0.00117	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—lymphatic system cancer	0.000344	0.00116	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000339	0.00115	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—lymphatic system cancer	0.000336	0.00114	CcSEcCtD
Rivaroxaban—Hypotension—Methotrexate—lymphatic system cancer	0.000323	0.00109	CcSEcCtD
Rivaroxaban—Dyspnoea—Methotrexate—lymphatic system cancer	0.000309	0.00104	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—lymphatic system cancer	0.000305	0.00103	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000299	0.00101	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—lymphatic system cancer	0.000298	0.00101	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—lymphatic system cancer	0.000296	0.000999	CcSEcCtD
Rivaroxaban—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000285	0.000963	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000283	0.000956	CcSEcCtD
Rivaroxaban—Urticaria—Methotrexate—lymphatic system cancer	0.000275	0.000928	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—lymphatic system cancer	0.000274	0.000924	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000255	0.000861	CcSEcCtD
Rivaroxaban—Asthenia—Methotrexate—lymphatic system cancer	0.000248	0.000838	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—lymphatic system cancer	0.000245	0.000827	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—lymphatic system cancer	0.000237	0.0008	CcSEcCtD
Rivaroxaban—Dizziness—Methotrexate—lymphatic system cancer	0.000229	0.000773	CcSEcCtD
Rivaroxaban—Vomiting—Methotrexate—lymphatic system cancer	0.00022	0.000743	CcSEcCtD
Rivaroxaban—Rash—Methotrexate—lymphatic system cancer	0.000218	0.000737	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—lymphatic system cancer	0.000218	0.000736	CcSEcCtD
Rivaroxaban—Headache—Methotrexate—lymphatic system cancer	0.000217	0.000732	CcSEcCtD
Rivaroxaban—Nausea—Methotrexate—lymphatic system cancer	0.000206	0.000694	CcSEcCtD
